GTR 94997504
Bids Are Invited For Acquisition Cancer Medicines Group And
ICB — International Competitive Bid
Closed
South America
Tender Information
GTR Reference
94997504
Tendering Authority
Subscribe to view
Tender No
039/25/2025
Financer Name
Self-Funded
Work Title
Bids Are Invited For Acquisition Cancer Medicines Group And
Bid Type
ICB — International Competitive Bid
Country
Subscribe to view
Geographical Region
South America
Political Region
BRIC,G20
Last Date of Bid Submission
05-05-2025
Closed
Work Detail
Pharmacological Group: Antineoplastic, Active Principle: Azacitidine, Pharmaceutical Form: Injectable Po, Concentration/Dosage: 100, Unit: Mg, Volume: N/A, Presentation: Vial: N/A, Active Principle: Bevacizumab, Pharmaceutical Form: Injectable Solution, Concentration/Dosage: 25, Mg/Ml, Volume: 4Ml, Accessory: Not Located, Volume: 16Ml, Active Principle: Bleomycin Sulfate, Concentration / Dosage: 15, Unit: U, Volume: Not Applicable, Accessory: N / D, Active Principle: Bortezomib, Concentration / Dosage: 3, 5, 04/04/2025, Active Principle: Cabazitaxel, Concentration: 1, 60, 60 5Ml, Presentation: F / A, Accessory: Diluent, Active Principle: Carboplatin, Pharmaceutical Form: N / D, Concentration / Dosage: 150, Active Principle: Dacarbazine, Concentration / Dosage: 200, Accessory: Non -Applicable, Active Principle: Etooposid, Concentration / Dosage: 20, Volume: 5Ml, Pharmacological Group Active: Filgrastim, Concentration / Dosage: 300, Unit: Mcg, Volume: 1Ml, Active Principle: Fulvest, Concentration / Dosage: 50, Presentation: Filled Syringe, Active Principle: Gencitabine Hydrochloride, Concentration / Dosage: 1, Unit: G, Volume: 50Ml, Active Principle: Irinotecan, Pharmacological Group: Antineoplastic/Enzyme Inhibitors, Active Principle: Ixazomibe Citrate, Pharmaceutical Form: Hard Capsule, Concentration/Dosage: 4, Presentation: Form Supply: Unit, Active Principle: Methotrexate, Volume: 2Ml, Active Principle: Methotrexate Of Sodium, Pharmaceutical Form: For Injectable Solution Without Preservative, Concentration / Dosage: 500, Pharmacological Group: Immunostimulant, Active Principle: Mycobacterium Bovis, Pharmaceutical Form: Injectable Po, Concentration / Dosage: 40, Ampoule, Form Supply: Ampoule, Active Principle: Pemetrexede, Active Principle: 10 Ml, 50 Ml, 50 Ml, Active Principle: Trastuzumab, Concentration / Dosage: 440, Active Principle: Vimblastin Sulfate, Concentration / Dosage: 10, Active Principle: Vinistine Sulfate, Volume: 1 Ml, Presentation: Bottle / Ampoule
Key Value
Tender Value
17,623,719 - BRL
Tender Documents
Global Tender Document
3b373f71-49d0-443d-be8b-cd396e648491.html
Attachments
Additional Details Available on Click
- Tendering Authority
- Publication Document (Tender Document / Tender Notice)
Disclaimer
We take all possible care for accurate & authentic tender information. However, users are requested to refer to the original Tender Notice / Tender Document published by the Tender Issuing Agency before taking any decision regarding this tender.